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Abstract
Purpose—To assess clinical characteristics and trends in valganciclovir use among infants 
diagnosed with congenital cytomegalovirus (CMV) disease in the United States.
Methods—We analyzed 2009–2015 medical claims from Truven Health MarketScan® 
Commercial Claims and Encounters and Medicaid databases. We identified infants with a live 
birth code in the first claim who were enrolled for at least 45 days. Among infants diagnosed with 
congenital CMV disease, identified by an ICD-9-CM or ICD-10-CM code of congenital CMV 
infection or CMV disease within 45 days of birth, we assessed codes for CMV-associated clinical 
condition within the same period, and hearing loss and valganciclovir claims within the first 180 
days.
Findings—In the commercial and Medicaid databases, we identified 257 (2.5/10,000) and 445 
(3.3/10,000) infants diagnosed with congenital CMV disease, respectively, among whom 135 
(53%) and 282 (63%) had ≥1 CMV-associated condition, 30 (12%) and 32 (7%) had hearing loss, 
and 41 (16%) and 78 (18%) had valganciclovir claims. Among infants with congenital CMV 
disease who had valganciclovir claims, 37 (90%) among commercially-insured infants and 68 
(87%) among Medicaid-insured infants had ≥1 CMV-associated condition and/or hearing loss. 
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From 2009 to 2015, the proportion with valganciclovir claims increased from 0% to 29% among 
commercially-insured infants and from 4% to 37% among Medicaid-insured infants (p<0.0001).
Implications—During 2009–2015, there was a strong upward trend in valganciclovir claims 
among insured infants who were diagnosed with congenital CMV disease, the majority of whom 
had CMV-associated conditions and/or hearing loss.
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INTRODUCTION
Cytomegalovirus (CMV) is one of the most common congenital infections and can cause 
sensorineural hearing loss (SNHL), cognitive delays, and cerebral palsy1. The prevalence of 
congenital CMV infection in the United States is estimated to be 0.5%2. Approximately 10–
15% of infected infants present with symptomatic disease at birth, which may include 
microcephaly, hepatosplenomegaly, petechiae, chorioretinitis, and jaundice3. Infants with 
symptomatic congenital CMV disease are also more likely to present with SNHL at birth or 
later, as well as cognitive delays and motor impairments3, 4. Most cases of symptomatic 
congenital CMV disease are likely undiagnosed in part because symptoms at birth are non-
specific, and laboratory diagnosis must be performed within the first 3 weeks of life1.
The first pilot study examining the use of intravenous (IV) ganciclovir for treatment of 
infants with symptomatic congenital CMV disease was published in 19945. In 2003, data 
from a phase III trial of IV ganciclovir use for 6 weeks showed improved hearing and 
neurodevelopmental outcomes in treated infants, though treatment was associated with 
higher rates of neutropenia6, 7. Subsequent studies assessed the effect of the oral pro-drug 
valganciclovir8, 9. In 2012, the American Academy of Pediatrics (AAP) recommended that 
ganciclovir and valganciclovir treatment should be limited to neonates with symptomatic 
congenital CMV disease with central nervous system (CNS) involvement who were able to 
start treatment within the first month of life10. In 2015, the AAP reviewed the antiviral 
treatment recommendation based on data from a phase III trial of 6-month vs. 6-week 
treatment with valganciclovir for infants with symptomatic congenital CMV disease with or 
without CNS involvement that showed modest improvement of hearing and 
neurodevelopmental outcomes at 24 months, and a lower rate of neutropenia than seen in the 
study with IV ganciclovir9, 11.
The extent to which antivirals are used for treatment of infants with symptomatic congenital 
CMV disease in the United States is unknown. We assessed clinical characteristics and 
trends in valganciclovir use among infants diagnosed with congenital CMV disease in the 
United States during 2009–2015 using a large national healthcare claims database.
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METHODS
Data Source
We used 2 Truven Health MarketScan® healthcare claims databases: 1) 2009–2015 
Commercial Claims and Encounters Database and 2) 2009–2015 Multi-State Medicaid 
database (Truven Health MarketScan Databases, IBM Watson Health, Ann Arbor, MI)12, 13. 
The commercial databases include data for approximately 30–40 million employees and 
their beneficiaries each year from all US states covered by employer sponsored insurance. 
The Medicaid databases include data for approximately 6–13 million beneficiaries from 8–
12 unidentified states. Both commercial and Medicaid databases include information on 
enrollment, inpatient and outpatient services, and outpatient pharmaceutical claims data for a 
subset of enrollees in the Commercial databases, including information on age and sex, 
clinical characteristics, medical procedures and pharmaceutical treatment. Enrollees are 
assigned a de-identified unique number which allows linkage of claims over time. The 
commercial databases contain a family identifier that allows linkage of family members 
enrolled together under a single subscriber policy; we used this variable to identify mothers 
of commercially-insured infants in order to calculate maternal age. Only the Medicaid 
databases include information on race/ethnicity. This study of de-identified data was 
determined not to require institutional review board review.
Case Definitions
Our study cohort was created by first identifying infants with congenital CMV disease who 
met our study criteria. We then pulled all their claims with a CMV-associated condition, 
hearing loss, brain imaging procedures, and valganciclovir treatment.
For this study, criteria for inclusion were infants who were continuously enrolled for at least 
45 days after their first claim with an International Classification of Disease, 9th or 10th 
Revisions, Clinical Modification (ICD-9-CM or ICD-10-CM) or diagnosis-related group 
code for live birth and for whom outpatient pharmaceutical claims data were available. 
Infants who died in the hospital before 45 days were excluded from the analysis. For infants 
enrolled in Medicaid, we included those with known basis of Medicaid eligibility, which 
included children in low-income families, children born to mothers on Medicaid (these 
children are automatically covered for their first year of life), and disabled individuals who 
qualify for the Supplemental Security Income program; states have flexibility in their 
Medicaid programs to include additional groups14.
The diagnosis of congenital CMV infection must be confirmed by laboratory testing within 
2 to 3 weeks of birth, and laboratory results were not captured by claims databases. We 
identified infants diagnosed with congenital CMV disease by the presence of an ICD-9-CM 
or ICD-10-CM code of congenital CMV infection or CMV disease within 45 days. We used 
45 days because of potential delays in submission of a claim. Among infants diagnosed with 
congenital CMV disease, we assessed the frequency of CMV-associated conditions, hearing 
loss, brain imaging procedures, and valganciclovir treatment. Using ICD-9-CM or ICD-10-
CM codes, we also assessed the following CMV-associated conditions within 45 days: 
jaundice, petechiae, hepatomegaly, splenomegaly, microcephaly, thrombocytopenia, 
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chorioretinitis, and brain abnormalities (Appendix Table 1). We defined hearing loss by the 
presence of either ≥3 medical encounters with an ICD-9-CM or ICD-10-CM code of hearing 
loss or ≥1 claim with a Current Procedural Terminology (CPT) code of hearing aid or 
cochlear implant within 180 days. Brain imaging procedures included head computed 
tomography (CT) scans or magnetic resonance imaging (MRI) using CPT codes recorded 
within 45 days. We assessed valganciclovir treatment by the presence of any valganciclovir 
claim within 180 days using codes listed in the National Drug Code Directory (Appendix 
Table 1).
Analysis
We performed all analyses using SAS version 9.3 (SAS Institute, Cary, North Carolina). We 
assessed trends in valganciclovir claims over time using the Cochrane Armitage trend test. 
We conducted univariate analyses to compare selected characteristics between infants 
diagnosed with congenital CMV infection among the commercially-insured and Medicaid-
insured infants, and to assess whether presence of any CMV-associated conditions or hearing 
loss was associated with valganciclovir treatment using Pearson chi square or Fisher’s exact 
test. We considered results with a p-value <0.05 as statistically significant.
RESULTS
We identified 1,163,112 commercially-insured infants and 1,357,945 Medicaid-insured 
infants, among whom 257 (2.5/10,000 infants) and 445 (3.3/10,000 infants) were diagnosed 
with congenital CMV disease, respectively. The proportion diagnosed with congenital CMV 
disease significantly increased during the study period among commercially-insured infants 
(p=0.0155 for test of trend; regression slope=2.03), but not among Medicaid-insured infants 
(p=0.3755 for test of trend; regression slope = −3.53) [Figure 1A]. Demographic 
characteristics of all infants who met the study criteria, infants diagnosed with congenital 
CMV disease, and those with congenital CMV disease and valganciclovir treatment are 
shown in Table 1. The median maternal age was 32 years (range, 20–45 years) for 
commercially-insured infants with congenital CMV disease; this information was not 
available for the Medicaid-insured infants. Five (0.7%) infants with congenital CMV disease 
died in hospitals within 142 days—two commercially-insured and three Medicaid-insured 
infants.
Many of the infants with congenital CMV disease had ≥1 CMV-associated condition, 135 
(53%) in the commercially-insured group and 282 (63%) in the Medicaid-insured group 
[Table 2]. Among all 257 and 445 commercially-insured and Medicaid-insured infants, 
respectively, diagnosed with congenital CMV disease, 30 (12%) and 32 (7%) had hearing 
loss and 51 (20%) and 99 (22%) had a neurological abnormality (microcephaly, 
chorioretinitis and/or brain abnormality). Among a subset of infants with congenital CMV 
disease enrolled continuously for the first 180 days of life, 25 out of 203 (12%) 
commercially-insured and 28 out of 294 (10%) Medicaid-insured infants had hearing loss. 
The proportion of infants with congenital CMV disease who had undergone CT declined 
significantly during 2009–2015, from 17% to 7% among commercially-insured and from 
21% to 8% among Medicaid-insured infants. Although the proportion of those who had 
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undergone MRI increased from 6% to 11% among commercially-insured and from 9% to 
16% among Medicaid-insured infants, this increase was not statistically significant. Among 
a subset of infants with congenital CMV disease who had undergone brain imaging, 52% 
(28/54) commercially-insured and 35% (32/91) Medicaid-insured infants had brain 
abnormalities.
Overall, among infants with congenital CMV disease, 41 (16%) commercially-insured and 
78 (18%) Medicaid-insured infants had valganciclovir treatment. The proportion of infants 
with congenital CMV disease who had valganciclovir treatment increased significantly 
during 2009–2015, from 0% (0/35) to 29% (8/28) among commercially-insured infants, and 
from 4% (3/67) to 37% (28/76) among Medicaid-insured infants (p<0.0001) [Figure 1B]. 
The median age at the first valganciclovir treatment claim was 24 days (range, 0–131) 
among commercially-insured infants, and 30 days (range, 5–163) among Medicaid-insured 
infants; 76% (31/41) and 73% (57/78), respectively, had their first valganciclovir treatment 
claim within 45 days of life. The median interval between the first valganciclovir claim and 
last valganciclovir claim for 119 infants with congenital CMV disease and valganciclovir 
treatment in this study was 61 days (median of 98 days for commercially-insured and 44 
days for Medicaid-insured infants), with the interval being < 6 weeks for 43%, 6 weeks-6 
months for 53%, and >6 months for 4%.
The majority of infants with congenital CMV disease who had valganciclovir treatment had 
≥1 CMV-associated condition and/or hearing loss (90% and 87% among commercially and 
Medicaid-insured infants, respectively). Among infants with congenital CMV disease who 
had valganciclovir treatment, 2 (5%) commercially-insured and 3 (4%) Medicaid-insured 
infants had hearing loss without any other CMV-associated condition. Valganciclovir 
treatment among infants with congenital CMV disease was significantly associated with 
petechiae, splenomegaly, microcephaly, thrombocytopenia, brain abnormalities, any 
neurologic abnormality, ≥2 CMV-associated conditions, and hearing loss, in both 
commercially- and Medicaid-insured infants; with chorioretinitis among commercially-
insured infants only; and with hepatomegaly among Medicaid-insured infants only [Table 3]. 
When we restricted to infants with only 1 CMV-associated condition, valganciclovir 
treatment was significantly associated with infants with microcephaly alone among 
commercially insured infants with congenital CMV disease, and with jaundice alone or brain 
abnormalities alone among Medicaid insured infants.
DISCUSSION
In 2012, the AAP recommended that treatment with valganciclovir be considered for infants 
with symptomatic congenital CMV disease with CNS involvement10. Using a large national 
healthcare claims database, we found that approximately 20% of infants identified with 
congenital CMV disease in the United States were treated with valganciclovir, with an 
increasing trend during 2009–2015. We could not assess factors that were associated with 
increasing trends in valganciclovir treatment among infants with congenital CMV disease. 
However, we can speculate that these increases may be due to increased use of 
valganciclovir in place of IV ganciclovir because valganciclovir can be administered in an 
outpatient setting, and rates of neutropenia appear to be lower than with IV ganciclovir9. The 
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rise in valganciclovir may also be due in part to increased awareness among physicians and 
insurance coverage of antiviral treatment likely contributed to these increasing trends. The 
publication of studies on the use of valganciclovir to treat neonates with symptomatic 
congenital CMV disease starting in 2008, and AAP’s recommendation on antiviral treatment 
may have helped to increase awareness among physicians8–11.
Using convenience samples of commercially- and Medicaid-insured infants, we found the 
prevalence of congenital CMV disease was 2 to 3 per 10,000. The prevalence of congenital 
CMV disease was higher among infants with Medicaid insurance (3.3 per 10,000) compared 
to commercially-insured infants (2.5 per 10,000), which likely reflects a higher proportion of 
Medicaid infants with underlying conditions and risk factors associated with congenital 
CMV infection, such as non-White race, or other maternal characteristics, such as age or 
socioeconomic status, that could not be measured15. A study that looked at RSV 
hospitalizations among commercially and Medicaid insured infants also found higher rates 
of hospitalizations and more severe cases among Medicaid-insured infants16. Data from this 
study and others suggest that not all infants with symptomatic congenital CMV disease are 
diagnosed or captured using administrative healthcare claims17, 18. We observed a 
prevalence of symptomatic congenital CMV disease that was between one-half and one-third 
of the expected 5.0–7.5 per 10,000 prevalence in the United States2. One study by Diener et 
al.19 found that the proportion of diagnosed symptomatic congenital CMV cases may be as 
high as 30%, though other studies have found this proportion to be much lower, with <10% 
of symptomatic cases diagnosed17, 18, 20.
Studies evaluating the sensitivity, specificity, and accuracy of administrative healthcare 
claims to capture certain conditions among infants have found that specificity and sensitivity 
can vary greatly by condition and by whether the claim was identified from an inpatient or 
outpatient setting21–26. Because our study relies on use of administrative data based on 
convenience samples of infants with commercial or Medicaid insurance, our study had a 
number of limitations. Our data may not be generalizable to all US infants, and Medicaid 
data are from a select number of states. There may have been errors in the diagnostic and 
procedural coding for congenital CMV disease, CMV-associated conditions, brain 
abnormalities, and hearing loss. It is possible that infants with congenital CMV disease may 
have had CMV-associated conditions, such as intrauterine growth restriction or abnormal 
brain imaging findings that were not included in our study or captured in the claims. 
Laboratory test results and medical records were unavailable to confirm the diagnosis of 
congenital CMV disease. We also may have missed deaths and hearing loss that occurred 
after the study observation time.
It is possible that we did not accurately capture data within the first 45 days because we did 
not have birth date and therefore had to approximate the birth date using the first claim with 
a live birth code. There may also be a delay in the enrollment of a newborn in a health plan. 
As a result, we may have missed newborns with a CMV diagnosis or valganciclovir 
treatment using the 45-day continuous enrollment criteria. Using another enrollment criteria 
(infants with a newborn inpatient claim and enrolled at 45 days of life), we found no 
changes in the trends of CMV diagnosis or valganciclovir treatment among commercial- or 
Medicaid-insured infants. Lastly, we did not have access to inpatient antiviral treatment, so 
Leung et al. Page 6
Clin Ther. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
we were unable to evaluate trends in IV ganciclovir use and complete history of antiviral 
treatment over time.
Many of the infants with congenital CMV disease in this study had a CMV-associated 
condition and/or hearing loss. Most infants identified with congenital CMV disease who also 
had valganciclovir treatment had CMV-associated conditions, among which petechiae, 
splenomegaly, microcephaly, thrombocytopenia, hearing loss, and brain abnormalities were 
significantly associated with valganciclovir treatment. We found that the majority of 
congenital CMV cases were treated within the first 45 days: 76% among the commercially-
insured and 73% among the Medicaid-insured infants. These findings suggest that current 
management of a majority of infants with congenital CMV disease is in line with the 
recommendations of the American Academy of Pediatrics, which consists of antiviral 
treatment for management of symptomatic congenital CMV disease for infants who are able 
to start treatment within the first month11. In a minority of treated infants, underreporting of 
CMV-associated conditions or treatment of asymptomatic infants with hearing loss only are 
possible. There has been limited clinical experience of use of antivirals in infants with 
asymptomatic congenital CMV infection with isolated hearing loss27–29. However, this has 
not been systematically evaluated in a randomized controlled trial or study, thus, there is no 
evidence to support treatment of infants with asymptomatic congenital CMV infection.
Symptomatic congenital CMV disease frequently involves the central nervous system and 
results in neurodevelopmental sequelae1, 4, 30–32. Neuroimaging is useful to inform 
prognosis and guide clinical management of infants with congenital CMV disease33. Infants 
with congenital CMV disease and brain abnormalities suggesting tissue destruction (i.e. 
intracranial calcifications, white matter lucency) or dysplastic growth (i.e. lissencephaly, 
pachygyria) are at increased risk of intellectual disability and SNHL34. In this study, we 
found that approximately 20% of infants with congenital CMV disease had CT or MRI 
performed within the first 45 days, among whom 41% had a diagnosis of at least one brain 
abnormality. We also found a decreasing trend over time in use of head CT for neuroimaging 
evaluation of infants with congenital CMV disease, among both the commercially- and 
Medicaid-insured infants, and an increasing, albeit non-significant, trend in MRI use. These 
findings are consistent with more recent recommendations for neuroimaging evaluation 
using MRI or ultrasound because CT scans can lead to high exposure to radiation3533, 36.
In the absence of surveillance or newborn screening for congenital CMV infection, 
administrative data can be useful to assess national trends in diagnosis and management of 
infants with symptomatic congenital CMV disease. Further studies are needed to assess the 
accuracy, sensitivity and specificity of using administrative claims data for identifying 
infants with congenital CMV infection and evaluating factors associated with increasing 
trends in valganciclovir use.
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Figure 1. 
Rate of congenital CMV disease and proportion with valganciclovir among infants with 
congenital CMV disease, MarketScan Commercial Claims and Encounters and Medicaid 
Databases 2009–2015
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Appendix Table 1
List of Diagnostic, Procedural, and Drug Codes
Code(s) Code Description
Newborn Codes
ICD-9-CM V30–31, V33–4, V36, V37, V39; ICD-10 CM Z38.xx Live birth
DRG 791–795 Prematurity with and without Major Problems, 
Full Term Neonate with Major Problems, Neonate 
with Other Significant Problems, Normal 
Newborn
Congenital cytomegalovirus (CMV), CMV Disease, and CMV-Associated Conditions
ICD-9-CM 771.1; ICD-10 CM P35.1 Congenital CMV Infection
ICD-9-CM 078.5; ICD-10-CM B25.x CMV Disease
ICD-9-CM 774; ICD-10-CM P58.x or P59.x Jaundice
ICD-9-CM 772.6, 782.7; ICD-10-CM P54.5; Petechiae
ICD-9-CM 751.69, 789.1; ICD-10-CM Q44.7, R16.0, R16.2, B25.1 Hepatomegaly
ICD-9-CM 759.0, 789.2; ICD-10-CM Q89.09, R16.1, R16.2 Splenomegaly
ICD-9-CM 742.1; ICD-10-CM Q02 Microcephaly
ICD-9-CM 776.1, 776.2, 287.3–287.5; ICD-10-CM P60, P61.0, D69.4x-D69.6x Thrombocytopenia
ICD-9-CM 363.0–3; ICD-10-CM H30.0x, H30.1x, H30.89x, H30.9x, H31.00x Chorioretinitis
ICD-9-CM 348.89, 742.2–742.4, 793.0; ICD-10-CM G91.xx, G93.89, G93.9, Q03.xx, 
Q04.xx, R90.82
Brain abnormalities
Hearing Loss (Diagnostic codes)
ICD-9-CM 389.1x-389.9; ICD-10-CM H90.3x-H90.8x, H91.x Hearing loss
Hearing Aid or Cochlear Implant Codes (Procedural codes):
CPT 92590–92595; HCPCS V5010, V5011, V5014, V5020, V5060, V5090, V5140, 
V5160, V5241, V5247, V5253, V5257, V5261, V5264, V5275, V5298; ICD-9 v3 V53.2; 
ICD-10 Z46.1
Hearing aid
CPT 69710, 69930, 92510, 92601, 92602; HCPCS L8614 Cochlear Implant
Brain imaging (Procedural codes):
CPT 70450, 70460, 70470, 70480, 70481, 70482 Computed tomography (CT)
CPT 70551–3 Magnetic Resonance Imaging (MRI)
Antiviral Treatment (Drug codes):
NDC 00004003822, 00004003909
00603633020, 54569610100
55111076260,
Valganciclovir Hydrochloride
68084096525, 00591257920, 31722083260, 42291087560, 50268078711, 50268078712, 
65862075360, 68084096595
Abbreviations: ICD-9-CM=International Classification of Diseases-9th revision, ICD-10-CM = International Classification of Diseases-10th 
revision, Clinical Modification; DRG=Diagnoses Related Group; HCPCS= Healthcare Common Procedure Coding System; CPT= Current 
Procedural Terminology (CPT) codes; ICD-9 v3 Procedural Codes; NDC=National Drug Code
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